Stockscreener 앱 받기
1.01
4.12%
0.04
시간 외 거래:
1.01
Vaccinex Inc 주식(VCNX)의 최신 뉴스
Vaccinex stock trades flat at USD 1.00 after a thin session - AD HOC NEWS
Vaccinex stock holds at 1.00 dollars as investors await fresh trial and earnings updates - AD HOC NEWS
Vaccinex Stock Price Forecast. Should You Buy VCNX? - StockInvest.us
VCNX stock needs fresh market context - ad-hoc-news.de
BCAB Stock Price and Chart — OTC:BCAB - TradingView
Vaccinex Inc. (VCNX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
MSN Money - MSN
School Vaccine Mandates - Encyclopedia Britannica
CHGA Stock Price and Chart — NASDAQ:CHGA - TradingView
Alzheimer’s Drug Targets Astrocytes, Not Amyloid: Pepinemab Advances to Phase 2b - Tech Times
Vaccinex to Present Novel Glial Biomarker Data for Pepinemab at AAIC 2026, Outlining Path to Phase 2b in Alzheimer's Disease - BioPharm International
Vaccinex to present new biomarker data and Phas... - Pluang
Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer’s Association International Conference in London on July 13, 2026 - The Manila Times
Vaccinex to Present New Biomarker Data From SIGNAL-AD Study Supporting Expanded Phase 2b Trial of Pepinemab in Early Alzheimer’s Disease - Quiver Quantitative
Vaccinex to show new Alzheimer’s biomarker data in London - Stock Titan
Vaccinex to Report New Biomarker Data and Plans for Phase - GlobeNewswire
If You Invested $1,000 in Vaccinex Inc (VCNX) - Stock Titan
ADTX Stock Price and Chart — OTC:ADTX - tradingview.com
Price to book forward of Vaccinex, Inc. – OTC:VCNX - TradingView
Price to earnings forward of Vaccinex, Inc. – OTC:VCNX - TradingView
Vaccinex, Inc. Actuals & Estimates (OTC:VCNX) - TradingView
Enterprise value to revenue forward of Vaccinex, Inc. – OTC:VCNX - TradingView
Price to sales forward of Vaccinex, Inc. – OTC:VCNX - TradingView
Agitation in Alzheimer's Disease Market to Register Immense Growth at a CAGR of 14.9% During the Forecast Period (2026-2036) | DelveInsight - PR Newswire UK
Vaccinex Inc stock (US91831V1026): Biotech small cap focuses on neurology and oncology after recent - Ad-hoc-news.de
Vaccinex, Inc.Common Stock (NQ: VCNX - The Chronicle-Journal
Vaccinex Inc (VCNX) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Vaccinex Inc (VCNX) Stock Earnings Transcripts - GuruFocus
Vaccinex Inc (VCNX) Stock Price & 30 Year Financial Data - GuruFocus
Vaccinex Inc stock (US91831V1026): Biotech innovator in neuroscience - AD HOC NEWS
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025 | VCNX Stock News - Quiver Quantitative
Vaccinex posts 2025 financial statements for clinical-stage biotech - Stock Titan
Vaccinex Reports 2025 Annual Financial Results - The Manila Times
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025 - Quiver Quantitative
Vaccinex Inc stock (US91831V1026): Is its immunotherapy pipeline strong enough to unlock biotech ups - AD HOC NEWS
LABT Stock Price and Chart — NASDAQ:LABT - TradingView
DCOY Stock Price and Chart — NASDAQ:DCOY - tradingview.com
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease - Yahoo Finance
Health Experts Slam Possible FDA ‘Black Box’ Warning for COVID Vaccines - Scientific American
BNBX Stock Price and Chart — NASDAQ:BNBX - TradingView
NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight - PR Newswire UK
GLP-1 Agonists Market to Show Impressive Growth at a CAGR of 10.8% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire
PPCB Stock Price and Chart — NASDAQ:PPCB - TradingView
Highest-Paid CEOs - AFL-CIO
Alzheimer’s Therapeutics Market on Upward Trajectory Across - GlobeNewswire
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting - Barchart.com
Vaccinex (VCNX) Stock Price, News & Analysis - Stock Titan
NBCO Stock Price, News & Analysis - Stock Titan
ENZOLYTICS (ENZC) Stock Price, News & Analysis - stocktitan.net
OCEA Stock Price, News & Analysis - Stock Titan
ADXS Stock Price, News & Analysis - Stock Titan
SRNE Stock Price, News & Analysis | Sorrento Therapeutics - Stock Titan
Vaccinex to Report Promising New Clinical Data Revealing - GlobeNewswire
Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
Can Vaccinex Survive After Nasdaq Exit? Key Details on Company's Future Strategy - Stock Titan
BPTH Stock Price and Chart — OTC:BPTH - TradingView
FBLG Stock Price and Chart — NASDAQ:FBLG - TradingView
Vaccinex, Inc. Financial Statements – OTC:VCNX - TradingView
VCNX Stock Price and Chart — OTC:VCNX - TradingView
Vaccinex Announces Receipt of Delisting Notification from Nasdaq - Taiwan News
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Vaccinex Inc (VCNX) Quarterly 10-Q Report - qz.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - PR Newswire
Capricor Therapeutics (CAPR) Faces 5% Drop Amid Industry Slump - GuruFocus
Vaccinex Stock Spikes On Promising Data On Alzheimer’s Drug Study: Retail Sentiment Brightens - Stocktwits
Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement - Wiley
Vaccinex issues new warrants, secures $6.2 million in funding - Investing.com
Vaccinex, Inc. Announces Resignation of Chrystyna Bedrij Stecyk as Director - marketscreener.com
0.05%
0.82%
자본화:
|
볼륨(24시간):